FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely, oncology, and can be used to treat tumors. This method comprises administering a therapeutic combination comprising a therapeutically effective amount of trastuzumab-MCC-DM1 and a therapeutically effective amount of pertuzumab as a combined composition or alternately to a mammal.
EFFECT: use of the invention makes it possible to treat tumors due to the synergistic effect of the combination.
11 cl, 22 tbl, 37 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
| COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION | 2008 |
|
RU2523890C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WITH DUOCARMICIN USED FOR TREATING ENDOMETRIAL CANCER | 2015 |
|
RU2686085C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| TREATING SYD985 PATIENTS WITH T-DM1 REFRACTORY CANCER | 2016 |
|
RU2728101C2 |
| TARGETED EXPOSURE TO TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER BY HER3-TARGETED NANOPARTICLES | 2015 |
|
RU2692104C2 |
